Sarepta Therapeutics and Nationwide Children’s Hospital Announce FDA Clearance of the IND Applica…

  • Post author:
  • Post category:BioPharma

Nationwide Children’s Hospital is on track to initiate a Phase 1/2a clinical trial in individuals with Duchenne muscular dystrophy by year-end 2017.
Source: BioSpace